A1H Stock Chart & Stats
€1.08
-€0.02(-2.08%)
At close: 4:00 PM EST
€1.08
-€0.02(-2.08%)
Day’s Range― - ―
52-Week Range€0.61 - €1.20
Previous CloseN/A
Volume0.00
Average Volume (3M)356.00
Market Cap
€51.65M
Enterprise Value€67.72M
Total Cash (Recent Filing)€4.72M
Total Debt (Recent Filing)€12.24M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding77,817,220
10 Day Avg. Volume792
30 Day Avg. Volume356
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)-13.62
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Proprietary IPOwning a proprietary microorganism provides a durable product differentiation and intellectual-property foundation. This creates barriers to entry for competitors, supports formulation-specific know-how, and enables licensing or exclusivity in target applications if regulatory approvals and commercialization progress.
Diversified End MarketsServing both agricultural crop protection/biostimulant and water/industrial contamination markets reduces single-market dependence. This structural diversification offers multiple commercialization pathways, spreading execution risk and increasing the chance to capture revenue from at least one market segment over the medium term.
Improving FCF TrendFree cash flow showed improvement in 2025 versus 2024, indicating early progress in reducing cash burn. While still negative, a multi-year improvement trajectory can enhance runway and make future financing or commercialization efforts more effective if the trend continues.
Bears Say
Revenue CollapseAnnual revenue effectively collapsed to zero in 2025 after a small 2024 base, signaling failed or stalled commercialization. Without consistent revenue generation, the firm cannot achieve scale to cover fixed costs, undermining sustainable margins and long-term business viability absent new sales or partnerships.
Balance Sheet FragilityEquity turned negative across 2023–2025 while debt increased materially, indicating elevated leverage and refinancing risk. Negative equity constrains financial flexibility, raises cost of capital, and makes future fundraises more dilutive or difficult, threatening long-term solvency if losses persist.
Persistent Cash BurnOperating cash flow has been negative every year and free cash flow remains below zero, implying ongoing reliance on external funding. Persistent cash burn pressures strategy and execution, increasing dilution or default risk if capital markets tighten or anticipated commercial milestones are delayed.
Amoeba SA News
A1H FAQ
What was Amoeba SA’s price range in the past 12 months?
Amoeba SA lowest stock price was €0.61 and its highest was €1.20 in the past 12 months.
What is Amoeba SA’s market cap?
Amoeba SA’s market cap is €51.65M.
When is Amoeba SA’s upcoming earnings report date?
Amoeba SA’s upcoming earnings report date is Sep 24, 2026 which is in 61 days.
How were Amoeba SA’s earnings last quarter?
Amoeba SA released its earnings results on Mar 26, 2026. The company reported -€0.066 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.066.
Is Amoeba SA overvalued?
According to Wall Street analysts Amoeba SA’s price is currently Overvalued.
Does Amoeba SA pay dividends?
Amoeba SA does not currently pay dividends.
What is Amoeba SA’s EPS estimate?
Amoeba SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amoeba SA have?
Amoeba SA has 77,817,220 shares outstanding.
What happened to Amoeba SA’s price movement after its last earnings report?
Amoeba SA reported an EPS of -€0.066 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.62%.
Which hedge fund is a major shareholder of Amoeba SA?
Currently, no hedge funds are holding shares in DE:A1H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Amoeba SA
Amoéba S.A. focuses on the development and commercialization of anti-microbial and anti-fungal products. The company's primary innovation centers on harnessing the unique properties of the Willaertia magna C2c Maky amoeba, which it is applying across various fields. These applications are designed to mitigate biological risks in critical areas like water purification, the treatment of human injuries, and safeguarding agricultural crops. Established in 2010, Amoéba S.A. is based in Chassieu, France.